bepridil has been researched along with Chronic Disease in 10 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of bepridil on silent myocardial ischemia and on eicosanoid metabolism, 10 patients with chronic stable angina underwent exercise treadmill testing and 48-hour ambulatory electrocardiographic monitoring both before and after 4 weeks of bepridil administration (150 mg/day)." | 9.07 | Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction. ( Hikita, H; Kanda, Y; Kurita, A; Maruyama, T; Mizuno, K; Nakamura, H; Nishioka, T; Takase, B; Uehata, A, 1994) |
| "The long-term efficacy of bepridil as once-a-day monotherapy was studied in 19 men with stable angina pectoris." | 9.06 | Long-term bepridil monotherapy for angina pectoris. ( Prasad, R; Sharma, MK; Teague, SM; Thadani, U; Voyles, W, 1988) |
| "Bepridil is highly effective in terminating persistent atrial fibrillation (AF)." | 7.75 | Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation. ( Isobe, M; Kobori, A; Kuwahara, T; Miyazaki, S; Sato, A; Takahashi, A; Takahashi, Y; Takei, A, 2009) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 7.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| " The most frequent adverse effects in both groups were nausea, asthenia, dizziness, headache and diarrhea." | 6.67 | Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group. ( Singh, BN, 1991) |
| "To investigate the effects of bepridil on silent myocardial ischemia and on eicosanoid metabolism, 10 patients with chronic stable angina underwent exercise treadmill testing and 48-hour ambulatory electrocardiographic monitoring both before and after 4 weeks of bepridil administration (150 mg/day)." | 5.07 | Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction. ( Hikita, H; Kanda, Y; Kurita, A; Maruyama, T; Mizuno, K; Nakamura, H; Nishioka, T; Takase, B; Uehata, A, 1994) |
| "The long-term efficacy of bepridil as once-a-day monotherapy was studied in 19 men with stable angina pectoris." | 5.06 | Long-term bepridil monotherapy for angina pectoris. ( Prasad, R; Sharma, MK; Teague, SM; Thadani, U; Voyles, W, 1988) |
| "Bepridil is highly effective in terminating persistent atrial fibrillation (AF)." | 3.75 | Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation. ( Isobe, M; Kobori, A; Kuwahara, T; Miyazaki, S; Sato, A; Takahashi, A; Takahashi, Y; Takei, A, 2009) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 3.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| " The most frequent adverse effects in both groups were nausea, asthenia, dizziness, headache and diarrhea." | 2.67 | Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group. ( Singh, BN, 1991) |
| "Bepridil is a unique calcium antagonist with a broad pharmacologic profile and demonstrated efficacy as an antianginal agent." | 2.38 | Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. ( Singh, BN, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyazaki, S | 1 |
| Kuwahara, T | 1 |
| Kobori, A | 1 |
| Takahashi, Y | 1 |
| Takei, A | 1 |
| Sato, A | 1 |
| Isobe, M | 1 |
| Takahashi, A | 1 |
| Hill, JA | 1 |
| O'Brien, JT | 1 |
| Scott, E | 1 |
| Conti, CR | 1 |
| Pepine, CJ | 1 |
| Takase, B | 1 |
| Kurita, A | 1 |
| Hikita, H | 1 |
| Uehata, A | 1 |
| Nishioka, T | 1 |
| Maruyama, T | 1 |
| Mizuno, K | 1 |
| Nakamura, H | 1 |
| Kanda, Y | 1 |
| Weiss, RJ | 1 |
| DiBianco, R | 1 |
| Singh, BN | 2 |
| Sharma, MK | 1 |
| Voyles, W | 1 |
| Prasad, R | 1 |
| Teague, SM | 1 |
| Thadani, U | 1 |
| Perelman, MS | 1 |
| McKenna, WJ | 1 |
| Rowland, E | 1 |
| Krikler, DM | 1 |
2 reviews available for bepridil and Chronic Disease
| Article | Year |
|---|---|
Bepridil treatment of chronic stable angina: a review of comparative studies versus placebo, nifedipine, and diltiazem.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Chronic Disease; Diltiazem; Female; Humans; Male; Meta-Analy | 1992 |
Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Arrhythmias, Cardiac; Bepridil; Chronic Disease; El | 1992 |
4 trials available for bepridil and Chronic Disease
| Article | Year |
|---|---|
Effects of bepridil on exercise tolerance in chronic stable angina: a double-blind, randomized, placebo-controlled, crossover trial.
Topics: Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical | 1984 |
Effects of bepridil on silent myocardial ischemia and eicosanoid metabolism in chronic stable angina pectoris after healing of myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Angina Pectoris; Arachidonic Acids; Bepridil; Chronic Dis | 1994 |
Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group.
Topics: Adult; Aged; Angina Pectoris; Bepridil; Chronic Disease; Diltiazem; Double-Blind Method; Drug Tolera | 1991 |
Long-term bepridil monotherapy for angina pectoris.
Topics: Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical | 1988 |
4 other studies available for bepridil and Chronic Disease
| Article | Year |
|---|---|
Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Catheter Ablation; Chronic Disease; Electroca | 2009 |
Bepridil and agranulocytosis.
Topics: Aged; Agranulocytosis; Angina Pectoris; Bepridil; Chronic Disease; Female; Humans; Male | 1993 |
Bepridil for angina pectoris.
Topics: Angina Pectoris; Bepridil; Chronic Disease; Clinical Trials as Topic; Humans | 1991 |
A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bepridil; Chron | 1987 |